Recent Company News

• 01:11 AM ET Feb 21, 2026
  

  StreetAccount Consensus Metrics Preview - ZAI Lab Q4 Earnings (HK$15.37, 0.00)

• 08:50 PM ET Feb 11, 2026
  

  NICE recommends Merck's Zejula for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy ($119.31, 0.00)

• 09:58 PM ET Feb 09, 2026
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 09:35 AM ET Feb 05, 2026
  

  $207B Market Shift: The Race for Fast Track Approval in Oncology

• 01:03 AM ET Feb 04, 2026
  

  StreetAccount Sector Summary - China Healthcare January Recap

• 10:05 AM ET Feb 02, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (193 total)

• 03:10 AM ET Feb 02, 2026
  

  StreetAccount Summary: Hong Kong Stocks reaching new 52-week highs/lows (25 total)

• 10:38 PM ET Feb 01, 2026
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (98 total)

• 10:05 AM ET Jan 30, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (163 total)

• 07:13 AM ET Jan 30, 2026
  

  EU's CHMP adopted a positive opinion recommending change to terms of marketing authorisation for medicinal product Zynyz ($101.08, 0.00)